Boston Scientific (NYSE:BSX) informed investors this week that it’s under investigation by the U.S. Attorney for the District of New Jersey over a cardiology devices company acquired 2 years ago.

Boston Scientific reported in its most recent quarterly report that it was served with a subpoena for information about its 2012 acquisition of BridgePoint Medical as well as sales and training activities for BridgePoint’s CrossBoss CTO-crossing catheter and Stingray CTO re-entry system.

The subpoena was served on July 11, 2014, according to an SEC filing, and Boston Scientific said that it’s cooperating with the authorities.

Boston Scientific signed with BridgePoint for an undisclosed amount in September 2012, saying at the time that the acquisition "is expected to build upon our rich product portfolio in cardiology and represents an important part of our growth strategy in this critical market."

The link between BridgePoint and Boston Scientific runs deep. BridgePoint’s then-CEO Denis Harrington spent 18 years at Boston Scientific, rising to head of sales for its cardiovascular and cardiac rhythm management business before taking the corner office at BridgePoint. BridgePoint co-founder & former COO Chad Kugler got his start as an engineer at Boston Scientific and former board member Mike Berman is also a Boston Scientific veteran.